|

L-carnitine Supplementation in Rheumatoid Arthritis Patients

RECRUITINGPhase 2Sponsored by German University in Cairo
Actively Recruiting
PhasePhase 2
SponsorGerman University in Cairo
Started2024-12-31
Est. completion2025-06
Eligibility
Age18 Years – 60 Years
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06753565

Summary

This study aims to evaluate the effect of l-carnitine as add- on therapy for improving the outcome in rheumatoid arthritis patients.

Eligibility

Age: 18 Years – 60 YearsHealthy volunteers accepted
Inclusion Criteria:

* age between 18-60 years old
* diagnosed of rheumatoid arthritis according to 2010 American College of Rheumatology/European League Against Rheumatism criteria for at least 6 months
* enrolled patients treated with one of more of conventional DMARDs for ≥ 6 months with stable dose for ≥ 1 month before start of the study
* active RA despite conventional DMARDs treatment (DAS28 ESR more than or equal 3.2)
* patient or legal representative should sign informed consent

Exclusion Criteria:

* pregnant or lactating female
* patients with liver dysfunction (\>1.5x the upper limit of normal value for ALT \& AST)
* Patients with kidney dysfunction (serum creatinine more than 1.2 mg/dl)
* Patients with any active infection or concurrent malignancy
* patients with uncontrolled medical conditions or other rheumatic diseases
* patients currently taking drugs that could interact with carnitine like: warfarin

Conditions2

ArthritisRheumatoid Arthritis (RA

Browse More Trials

Arthritis trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.